Hologic, Inc. (HOLX) 10-Year Financial Performance & Capital Metrics

HOLX • • Industrial / General

HealthcareMedical InstrumentsDiagnostic & Monitoring EquipmentDiagnostic Testing & Monitoring

AboutHologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.Show more

Revenue $4.03B
EBITDA $1.19B +20.1%
Net Income $790M +73.1%
EPS (Diluted) 3.32 +81.4%
Gross Margin 55.28% +7.5%
EBITDA Margin 29.57% +20.1%
Operating Margin 21.9% +32.0%
Net Margin 19.59% +73.1%
ROE 15.56% +68.8%
ROIC 12.23% +30.0%
Debt/Equity 0.52 -10.5%
Interest Coverage 7.23 +20.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓FCF machine: 28.4% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Good 3Y average ROE of 17.8%
✓Share count reduced 4.5% through buybacks
✓Healthy 5Y average net margin of 24.1%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y4.76%

5Y3.66%

3Y-10.56%

TTM1.29%

Profit (Net Income) CAGR

10Y46.53%

5Y-

3Y-25%

TTM-20.58%

EPS CAGR

10Y49.38%

5Y-

3Y-22.78%

TTM-18.03%

ROCE

10Y Avg13.09%

5Y Avg19.2%

3Y Avg13.39%

Latest11%

Peer Comparison

Diagnostic Testing & Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NNNNAnbio Biotechnology Class A Ordinary Shares	1.52B	34.59	617.68	21.95%	31.03%	29.08%	0.14%
DXRDaxor Corporation	69.03M	13.70	124.55	-93.84%	401.5%	9.78%	0.04%	0.02
BDXBecton, Dickinson and Company	59.36B	208.35	35.74	8.23%	7.68%	6.61%	4.5%	0.76
HOLXHologic, Inc.	16.73B	75.02	22.60	-0%	13.79%	11.5%	6.84%	0.52
GCTKGlucoTrack, Inc.	3.62M	3.98	0.07			-389.1%
QDELQuidelOrtho Corporation	2.4B	35.38	-1.16	-7.17%	-43.43%	-57.92%		0.90
KMTSKESTRA MEDICAL TECHNOLOGIES, LTD.	1.34B	22.98	-4.48	115.05%	-177.99%	-80.55%		0.22
OSUROraSure Technologies, Inc.	196.55M	2.74	-10.54	-54.17%	-47.92%	-16.64%	12%	0.04

Profit & Loss

	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Sales/Revenue+	2.71B	2.83B	3.06B	3.22B	3.37B	3.78B	5.63B	4.86B	4.03B	4.03B
Revenue Growth %	0.07%	0.05%	0.08%	0.05%	0.05%	0.12%	0.49%	-0.14%	-0.17%	-0%
Cost of Goods Sold+	1.27B	1.27B	1.44B	1.52B	2.06B	1.55B	1.84B	1.87B	1.96B	1.8B
COGS % of Revenue	0.47%	0.45%	0.47%	0.47%	0.61%	0.41%	0.33%	0.38%	0.49%	0.45%
Gross Profit+	1.43B	1.56B	1.62B	1.7B	1.31B	2.23B	3.8B	3B	2.07B	2.23B
Gross Margin %	0.53%	0.55%	0.53%	0.53%	0.39%	0.59%	0.67%	0.62%	0.51%	0.55%
Gross Profit Growth %	0.15%	0.09%	0.04%	0.05%	-0.23%	0.7%	0.7%	-0.21%	-0.31%	0.08%
Operating Expenses+	949.1M	1B	1.14B	1.19B	1.18B	1.12B	1.32B	1.36B	1.4B	1.35B
OpEx % of Revenue	0.35%	0.35%	0.37%	0.37%	0.35%	0.3%	0.23%	0.28%	0.35%	0.33%
Selling, General & Admin	624M	682.4M	841.9M	910.7M	897.2M	840.3M	994.4M	1.04B	987.6M	994.8M
SG&A % of Revenue	0.23%	0.24%	0.28%	0.28%	0.27%	0.22%	0.18%	0.21%	0.25%	0.25%
Research & Development	214.9M	232.1M	232.8M	218.7M	232.2M	222.5M	276.3M	283.4M	294.3M	272.8M
R&D % of Revenue	0.08%	0.08%	0.08%	0.07%	0.07%	0.06%	0.05%	0.06%	0.07%	0.07%
Other Operating Expenses	-11M	26.6M	12.9M	7.6M	52M	59.7M	44.8M	35.8M	121.2M	77.6M
Operating Income+	455.1M	548.6M	1.37B	-237.9M	134.4M	1.1B	2.48B	1.64B	668.4M	882.6M
Operating Margin %	0.17%	0.19%	0.45%	-0.07%	0.04%	0.29%	0.44%	0.34%	0.17%	0.22%
Operating Income Growth %	0.63%	0.21%	1.5%	-1.17%	1.56%	7.22%	1.24%	-0.34%	-0.59%	0.32%
EBITDA+	946.5M	1.01B	1.82B	242.4M	597.4M	1.48B	2.89B	2.07B	991.8M	1.19B
EBITDA Margin %	0.35%	0.36%	0.59%	0.08%	0.18%	0.39%	0.51%	0.43%	0.25%	0.3%
EBITDA Growth %	1.41%	0.07%	0.79%	-0.87%	1.46%	1.48%	0.95%	-0.28%	-0.52%	0.2%
D&A (Non-Cash Add-back)	491.4M	465.4M	449.2M	480.3M	463M	376M	406.9M	430.1M	323.4M	309M
EBIT	382.7M	570.6M	1.38B	-269.9M	-116.9M	1.12B	2.45B	1.68B	787.2M	987.2M
Net Interest Income+	-204.2M	-154.6M	-149.4M	-142.4M	-136.2M	-112.2M	-92.2M	-82.2M	9.4M	-13.4M
Interest Income	1.3M	700K	3.8M	6.3M	4.6M	4.3M	1.4M	12.9M	120.5M	108.7M
Interest Expense	205.5M	155.3M	153.2M	148.7M	140.8M	116.5M	93.6M	95.1M	111.1M	122.1M
Other Income/Expense	-277.9M	-133.3M	-139.7M	-180.7M	-296.3M	-103.1M	-119.2M	-52M	7.7M	-17.5M
Pretax Income+	177.2M	415.3M	1.23B	-418.6M	-95.3M	1B	2.36B	1.59B	676.1M	865.1M
Pretax Margin %	0.07%	0.15%	0.4%	-0.13%	-0.03%	0.27%	0.42%	0.33%	0.17%	0.21%
Income Tax+	45.6M	84.5M	475M	-307.3M	-55.1M	-108.6M	491.4M	286.2M	220.1M	75.6M
Effective Tax Rate %	0.74%	0.8%	0.61%	0.27%	0.42%	1.11%	0.79%	0.82%	0.67%	0.91%
Net Income+	131.6M	330.8M	755.5M	-111.3M	-40.2M	1.12B	1.87B	1.3B	456M	789.5M
Net Margin %	0.05%	0.12%	0.25%	-0.03%	-0.01%	0.3%	0.33%	0.27%	0.11%	0.2%
Net Income Growth %	6.61%	1.51%	1.28%	-1.15%	0.64%	28.74%	0.68%	-0.3%	-0.65%	0.73%
Net Income (Continuing)	131.6M	330.8M	755.5M	-111.3M	-203.6M	1.11B	1.87B	1.3B	456M	789.5M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	2.1M	0	0	0	0
EPS (Diluted)+	0.45	1.16	2.64	-0.40	-0.15	4.21	7.21	5.13	1.83	3.32
EPS Growth %	6.5%	1.58%	1.28%	-1.15%	0.63%	29.07%	0.71%	-0.29%	-0.64%	0.81%
EPS (Basic)	0.47	1.18	2.70	-0.40	-0.15	4.24	7.28	5.18	1.85	3.35
Diluted Shares Outstanding	289.54M	286.16M	285.65M	275.11M	269.41M	264.61M	259.71M	253.84M	248.83M	237.55M
Basic Shares Outstanding	280.57M	280.21M	279.81M	275.11M	269.41M	262.73M	257.05M	251.53M	246.77M	235.72M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Total Current Assets+	1.27B	1.33B	1.48B	1.72B	1.79B	2.22B	3.17B	3.86B	4.18B	3.82B
Cash & Short-Term Investments	492.7M	548.4M	540.6M	666.7M	601.8M	701M	1.17B	2.34B	2.72B	2.33B
Cash Only	492.7M	548.4M	540.6M	666.7M	601.8M	701M	1.17B	2.34B	2.72B	2.16B
Short-Term Investments	0	0	0	0	0	0	0	0	0	173.4M
Accounts Receivable	416.1M	447M	533.5M	579.2M	648.7M	1.03B	942.7M	617.6M	625.6M	600.4M
Days Sales Outstanding	56.15	57.6	63.66	65.7	70.32	99.45	61.09	46.36	56.66	54.37
Inventory	283.1M	274.7M	331.6M	384.1M	444.9M	395.1M	501.2M	623.7M	617.6M	679.8M
Days Inventory Outstanding	81.22	78.99	84.18	92.16	78.86	93.11	99.61	122.04	115.08	137.66
Other Current Assets	53.6M	39.6M	50.5M	61.5M	62.8M	58.5M	528.8M	232.2M	187.2M	156.2M
Total Non-Current Assets+	6.4B	5.99B	6.5B	5.51B	4.82B	4.97B	5.75B	5.21B	4.95B	5.33B
Property, Plant & Equipment	457.1M	460.2M	472.8M	478.2M	470.9M	572.2M	648.3M	550.5M	579.7M	630M
Fixed Asset Turnover	5.92x	6.16x	6.47x	6.73x	7.15x	6.60x	8.69x	8.83x	6.95x	6.40x
Goodwill	2.81B	2.8B	3.17B	2.53B	2.56B	2.66B	3.28B	3.24B	3.28B	3.44B
Intangible Assets	3.02B	2.64B	2.75B	2.4B	1.46B	1.31B	1.66B	1.28B	888.6M	844.6M
Long-Term Investments	25M	3.5M	3M	8.8M	54.1M	11.4M	9.5M	5.5M	15.5M	150.7M
Other Non-Current Assets	63.2M	60.9M	72.6M	76M	83.3M	409M	130.7M	119.9M	133.1M	135.5M
Total Assets+	7.67B	7.32B	7.98B	7.23B	6.61B	7.2B	8.92B	9.07B	9.14B	9.16B
Asset Turnover	0.35x	0.39x	0.38x	0.45x	0.51x	0.52x	0.63x	0.54x	0.44x	0.44x
Asset Growth %	-0.09%	-0.05%	0.09%	-0.09%	-0.09%	0.09%	0.24%	0.02%	0.01%	0%
Total Current Liabilities+	944M	901.9M	1.87B	1.4B	1.07B	1.24B	1.33B	937.7M	1.21B	1.04B
Accounts Payable	117M	156.9M	166.6M	192.2M	186.5M	178.8M	215.9M	197.7M	175.2M	203.8M
Days Payables Outstanding	33.57	45.11	42.29	46.12	33.06	42.13	42.91	38.68	32.64	41.27
Short-Term Debt	391.2M	296M	1.15B	599.7M	271.4M	324.9M	313M	15M	287M	37.5M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	173.2M	176.4M	176.7M	196M	223.4M	262.7M	313.5M	292.2M	288.3M	289M
Current Ratio	1.34x	1.47x	0.79x	1.23x	1.68x	1.79x	2.39x	4.12x	3.47x	3.69x
Quick Ratio	1.04x	1.17x	0.61x	0.95x	1.26x	1.47x	2.01x	3.45x	2.95x	3.03x
Cash Conversion Cycle	103.8	91.47	105.55	111.74	116.12	150.42	117.79	129.71	139.09	150.76
Total Non-Current Liabilities+	4.65B	4.27B	3.33B	3.4B	3.26B	3.25B	3.37B	3.26B	2.92B	2.99B
Long-Term Debt	3.22B	3.05B	2.17B	2.7B	2.78B	2.71B	2.71B	2.81B	2.53B	2.5B
Capital Lease Obligations	34M	34.8M	56.8M	56.4M	52.9M	83M	88.9M	71.8M	62.4M	96.1M
Deferred Tax Liabilities	1.18B	982.6M	973.6M	498.2M	275.3M	305.5M	460.5M	342.4M	294.5M	371.2M
Other Non-Current Liabilities	166.9M	189.7M	106.1M	122.1M	128.7M	133.9M	92.6M	25.3M	13.2M	10.6M
Total Liabilities	5.59B	5.17B	5.19B	4.8B	4.33B	4.49B	4.7B	4.2B	4.12B	4.03B
Total Debt+	3.65B	3.38B	3.38B	3.36B	3.11B	3.15B	3.14B	2.92B	2.9B	2.66B
Net Debt	3.15B	2.83B	2.84B	2.7B	2.51B	2.45B	1.97B	582.1M	181.6M	497.8M
Debt / Equity	1.75x	1.58x	1.21x	1.38x	1.36x	1.16x	0.75x	0.60x	0.58x	0.52x
Debt / EBITDA	3.85x	3.33x	1.86x	13.87x	5.21x	2.13x	1.09x	1.41x	2.93x	2.23x
Net Debt / EBITDA	3.33x	2.79x	1.56x	11.12x	4.20x	1.65x	0.68x	0.28x	0.18x	0.42x
Interest Coverage	2.21x	3.53x	8.94x	-1.60x	0.95x	9.48x	26.50x	17.25x	6.02x	7.23x
Total Equity+	2.08B	2.14B	2.78B	2.43B	2.28B	2.71B	4.22B	4.88B	5.02B	5.13B
Equity Growth %	0.01%	0.03%	0.3%	-0.13%	-0.06%	0.19%	0.56%	0.16%	0.03%	0.02%
Book Value per Share	7.18	7.49	9.75	8.83	8.46	10.23	16.24	19.21	20.16	21.60
Total Shareholders' Equity	2.08B	2.14B	2.78B	2.43B	2.28B	2.71B	4.22B	4.88B	5.02B	5.13B
Common Stock	2.8M	2.9M	2.9M	2.9M	2.9M	2.9M	3M	3M	3M	3M
Retained Earnings	-3.47B	-3.14B	-2.38B	-2.49B	-2.69B	-1.57B	298.3M	1.6B	2.06B	2.85B
Treasury Stock	0	-250M	-450.1M	-725.9M	-926M	-1.58B	-1.99B	-2.53B	-3.04B	-3.85B
Accumulated OCI	-14.5M	-32.3M	-16.2M	-25.5M	-42.3M	-49.7M	-59.1M	-238.2M	-147.6M	-111.5M
Minority Interest	0	0	0	0	0	2.1M	0	0	0	0

Cash Flow

	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Cash from Operations+	786.1M	787.2M	8.3M	732.9M	649.5M	896.6M	2.33B	2.13B	1.05B	1.29B
Operating CF Margin %	0.29%	0.28%	0%	0.23%	0.19%	0.24%	0.41%	0.44%	0.26%	0.32%
Operating CF Growth %	0.55%	0%	-0.99%	87.3%	-0.11%	0.38%	1.6%	-0.09%	-0.51%	0.22%
Net Income	131.6M	330.8M	755.5M	-111.3M	-40.2M	1.11B	1.87B	1.3B	456M	789.5M
Depreciation & Amortization	491.4M	465.4M	449.2M	480.3M	463.1M	376M	406.9M	430.1M	323.4M	309M
Stock-Based Compensation	59.3M	65.4M	68.2M	65M	62M	83.3M	65M	66.7M	79.6M	82.3M
Deferred Taxes	-148.8M	-155.8M	-357.2M	-477.3M	-231.7M	-94.4M	0	-166.2M	0	-72.1M
Other Non-Cash Items	154.1M	25M	-804.2M	802.4M	557.6M	57.5M	21.4M	38.9M	189.2M	92.4M
Working Capital Changes	98.5M	56.4M	-103.2M	-26.2M	-161.3M	-636.3M	-34.4M	454.2M	3M	84.1M
Change in Receivables	-30.3M	-31.8M	-41.5M	-38.2M	-76.5M	-427.1M	110.9M	272.3M	-1.5M	41M
Change in Inventory	43.9M	7.6M	-11.6M	-50.6M	-63M	-25.3M	-84.1M	-136.6M	-4.9M	-47.4M
Change in Payables	25.5M	40.1M	-10.6M	23.9M	-5.5M	-4.9M	0	-14.4M	0	22.2M
Cash from Investing+	-86.1M	-68.4M	285.8M	-195.2M	-280.7M	-141.6M	-1.33B	-206.3M	-152.1M	-781M
Capital Expenditures	-89.4M	-98.5M	-107.6M	-105.6M	-113.6M	-156.4M	-177.7M	-127.2M	-150.2M	-72.4M
CapEx % of Revenue	0.03%	0.03%	0.04%	0.03%	0.03%	0.04%	0.03%	0.03%	0.04%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-300K	3M	-600K	-7.2M	-30.8M	-2.7M	12.8M	79.5M	3.1M	-143.6M
Cash from Financing+	-936.7M	-659.7M	-309.2M	-404.8M	-431.5M	-659.9M	-529.8M	-756M	-483.2M	-1.11B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	57.1M	233.1M	29.3M	16.5M	29M	25.2M	39.4M	-1.6M	34.6M	-20M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	696.7M	688.7M	-99.3M	627.3M	535.9M	740.2M	2.15B	2B	901M	1.15B
FCF Margin %	0.26%	0.24%	-0.03%	0.19%	0.16%	0.2%	0.38%	0.41%	0.22%	0.28%
FCF Growth %	0.63%	-0.01%	-1.14%	7.32%	-0.15%	0.38%	1.91%	-0.07%	-0.55%	0.27%
FCF per Share	2.41	2.41	-0.35	2.28	1.99	2.80	8.29	7.87	3.62	4.82
FCF Conversion (FCF/Net Income)	5.97x	2.38x	0.01x	-6.58x	-16.16x	0.80x	1.25x	1.63x	2.31x	1.63x
Interest Paid	143M	104M	102.4M	122.1M	132.5M	109.5M	93.2M	99.7M	105.4M	0
Taxes Paid	168.7M	184.8M	867.8M	178.2M	180.6M	265.9M	0	36.2M	0	137.9M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	6.35%	15.67%	30.67%	-4.27%	-1.71%	44.73%	54.04%	28.63%	9.22%	15.56%
Return on Invested Capital (ROIC)	6.29%	8.06%	19.39%	-3.32%	2.03%	16.67%	32.79%	21.12%	9.41%	12.23%
Gross Margin	52.96%	55.19%	52.99%	52.73%	38.85%	58.98%	67.39%	61.64%	51.4%	55.28%
Net Margin	4.87%	11.68%	24.7%	-3.46%	-1.19%	29.53%	33.23%	26.77%	11.31%	19.59%
Debt / Equity	1.75x	1.58x	1.21x	1.38x	1.36x	1.16x	0.75x	0.60x	0.58x	0.52x
Interest Coverage	2.21x	3.53x	8.94x	-1.60x	0.95x	9.48x	26.50x	17.25x	6.02x	7.23x
FCF Conversion	5.97x	2.38x	0.01x	-6.58x	-16.16x	0.80x	1.25x	1.63x	2.31x	1.63x
Revenue Growth	6.89%	4.72%	7.98%	5.2%	4.64%	12.15%	49.14%	-13.66%	-17.12%	-0%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Diagnostics	1.21B	1.24B	1.2B	1.15B	-	2.1B	3.69B	3.02B	-	1.78B
Diagnostics Growth	-	2.07%	-3.22%	-4.15%	-	-	75.78%	-18.31%	-	-
Breast Health	1.06B	1.11B	1.14B	1.22B	-	1.15B	1.35B	1.23B	-	1.52B
Breast Health Growth	-	4.65%	2.29%	7.02%	-	-	17.40%	-9.21%	-	-
Gyn Surgical	335.8M	393.1M	427.1M	422M	-	376.1M	488.1M	522.9M	-	641.3M
Gyn Surgical Growth	-	17.06%	8.65%	-1.19%	-	-	29.78%	7.13%	-	-
Skeletal Health	94M	89.9M	88.8M	91.2M	-	81M	96.9M	93.6M	-	84.1M
Skeletal Health Growth	-	-4.36%	-1.22%	2.70%	-	-	19.63%	-3.41%	-	-
Consumables	-	-	-	-	1.79B	-	-	-	2.54B	-
Consumables Growth	-	-	-	-	-	-	-	-	-	-
Capital Equipment, Components and Software	-	-	-	-	-	-	-	-	740.5M	-
Capital Equipment, Components and Software Growth	-	-	-	-	-	-	-	-	-	-
Service	-	-	-	-	-	-	-	-	730.5M	-
Service Growth	-	-	-	-	-	-	-	-	-	-
Other Type of Revenue	-	-	-	-	-	-	-	-	20M	-
Other Type of Revenue Growth	-	-	-	-	-	-	-	-	-	-
Medical Aesthetics [Domain]	-	-	-	-	-	65.3M	-	-	-	-
Medical Aesthetics [Domain] Growth	-	-	-	-	-	-	-	-	-	-
Medical Aesthetics	-	-	207.5M	339.1M	-	-	-	-	-	-
Medical Aesthetics Growth	-	-	-	63.42%	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
United States	-	-	-	-	-	-	3.9B	3.47B	3.06B	3.02B
United States Growth	-	-	-	-	-	-	-	-11.13%	-11.82%	-1.11%
Europe	-	-	-	-	396M	569.8M	1.2B	888.5M	520.3M	532.7M
Europe Growth	-	-	-	-	-	43.89%	110.92%	-26.07%	-41.44%	2.38%
Asia-Pacific	-	-	-	-	-	-	365M	359.7M	255.7M	259.6M
Asia-Pacific Growth	-	-	-	-	-	-	-	-1.45%	-28.91%	1.53%
World	-	-	-	-	-	-	163.2M	146.7M	196.4M	213.9M
World Growth	-	-	-	-	-	-	-	-10.11%	33.88%	8.91%
Asia Pacific	-	-	-	-	286M	226.8M	-	-	-	-
Asia Pacific Growth	-	-	-	-	-	-20.70%	-	-	-	-
Gyn Surgical	335.8M	393.1M	427.1M	422M	-	-	-	-	-	-
Gyn Surgical Growth	-	17.06%	8.65%	-1.19%	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Hologic, Inc. (HOLX) has a price-to-earnings (P/E) ratio of 22.6x. This is roughly in line with market averages.

Growth & Financials

Hologic, Inc. (HOLX) reported $4.04B in revenue for fiscal year 2024. This represents a 126% increase from $1.79B in 2011.

Hologic, Inc. (HOLX) saw revenue decline by 0.0% over the past year.

Yes, Hologic, Inc. (HOLX) is profitable, generating $557.1M in net income for fiscal year 2024 (19.6% net margin).

Dividend & Returns

Hologic, Inc. (HOLX) has a return on equity (ROE) of 15.6%. This is reasonable for most industries.

Hologic, Inc. (HOLX) generated $938.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...